Literature DB >> 15670037

The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study.

J A Heit1, J L Sobell, H Li, S S Sommer.   

Abstract

While Factor V (FV) Leiden is a risk factor for venous thromboembolism (VTE), the incidence of VTE among FV Leiden carriers is uncertain. The objective of the study was to estimate the overall age-specific and pregnancy-related VTE incidence and the relative risk among FV Leiden carriers. In a community-based sample of 3424 south-eastern Minnesota residents, 230 (6.7%) were genotyped as FV Leiden carriers; 220 carriers (mean age = 68 years) could be matched to a non-carrier on age, gender, ethnicity and length of medical history. We performed a retrospective cohort study of carriers and non-carriers by reviewing the complete medical records in the community for demographic and baseline characteristics, pregnancies and live births, and first lifetime VTE. Over 14 722 person-years, 24 (10.9%) carriers developed VTE [overall incidence = 163 (95% CI 104, 242) per 100,000 person-years]. VTE incidence rates for ages 15-29, 30-44, 45-59 and > or = 60 years were 0, 61, 244 and 764 per 100,000 person-years, respectively (cumulative VTE incidence at age 65 years = 6.3%). VTE incidence for carriers did not differ significantly from that for non-carriers except for those > or = 60 years old (relative risk = 3.6; 95% CI 2.0, 6.0). There were 311 live births among 130 women carriers; no VTE events occurred during pregnancy or postpartum [incidence = 0 (95% CI 0, 1186) per 100,000 women-years]. Most FV Leiden carriers do not develop VTE. Among all carriers, those > or = 60 years old are at the highest risk for VTE. The incidence of VTE among asymptomatic women carriers during pregnancy is low and insufficient to warrant prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670037     DOI: 10.1111/j.1538-7836.2004.01117.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  18 in total

Review 1.  Achieving Multidisciplinary Collaboration for the Creation of a Pulmonary Embolism Response Team: Creating a "Team of Rivals".

Authors:  Christopher Kabrhel
Journal:  Semin Intervent Radiol       Date:  2017-03       Impact factor: 1.513

2.  Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study.

Authors:  Aneel A Ashrani; Rachel E Gullerud; Tanya M Petterson; Randolph S Marks; Kent R Bailey; John A Heit
Journal:  Thromb Res       Date:  2016-01-05       Impact factor: 3.944

3.  Thrombus stability explains the factor V Leiden paradox: a mouse model.

Authors:  S A Shaya; R J Westrick; P L Gross
Journal:  Blood Adv       Date:  2019-11-12

Review 4.  Management of venous thromboembolism in the elderly.

Authors:  Alex C Spyropoulos; Geno Merli
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

Review 6.  Environmental and Genetic Risk Factors Associated with Venous Thromboembolism.

Authors:  Marta Crous-Bou; Laura B Harrington; Christopher Kabrhel
Journal:  Semin Thromb Hemost       Date:  2016-10-20       Impact factor: 4.180

7.  Recurrent venous thromboembolism in a patient with heterozygous factor v leiden mutation.

Authors:  C Whitney White; Angela R Thomason; Valerie Prince
Journal:  Hosp Pharm       Date:  2014-09

Review 8.  Testing for thrombophilia: an evidence-based approach.

Authors:  L Merriman; M Greaves
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

Review 9.  The epidemiology of venous thromboembolism in the community: implications for prevention and management.

Authors:  John A Heit
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

10.  Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease.

Authors:  R P Naik; M B Streiff; C Haywood; J B Segal; S Lanzkron
Journal:  J Thromb Haemost       Date:  2014-10-18       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.